Cryoport (CYRX) Competitors

Arcutis Biotherapeutics (NASDAQ:ARQT) and Cryoport (NASDAQ:CYRX) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, community ranking, institutional ownership, media sentiment, earnings, dividends, profitability, valuation and risk.

Which has more volatility and risk, ARQT or CYRX?

Arcutis Biotherapeutics has a beta of 1.3, suggesting that its stock price is 30% more volatile than the S&P 500. Comparatively, Cryoport has a beta of 1.58, suggesting that its stock price is 58% more volatile than the S&P 500.

Which has preferable earnings & valuation, ARQT or CYRX?

Cryoport has higher revenue and earnings than Arcutis Biotherapeutics. Arcutis Biotherapeutics is trading at a lower price-to-earnings ratio than Cryoport, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arcutis Biotherapeutics	$59.61M	24.90	-$262.14M	-$1.79	-7.08
Cryoport	$226.11M	1.64	-$99.59M	-$3.38	-2.22

Is ARQT or CYRX more profitable?

Cryoport has a net margin of -70.08% compared to Arcutis Biotherapeutics' net margin of -140.97%. Cryoport's return on equity of -13.35% beat Arcutis Biotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Arcutis Biotherapeutics	-140.97%	-119.11%	-45.95%
Cryoport	-70.08%	-13.35%	-6.43%

Does the MarketBeat Community favor ARQT or CYRX?

Cryoport received 181 more outperform votes than Arcutis Biotherapeutics when rated by MarketBeat users. However, 65.26% of users gave Arcutis Biotherapeutics an outperform vote while only 65.15% of users gave Cryoport an outperform vote.

Company	Underperform	Outperform
Arcutis Biotherapeutics	Outperform Votes 62 65.26%	Underperform Votes 33 34.74%
Cryoport	Outperform Votes 243 65.15%	Underperform Votes 130 34.85%

Does the media refer more to ARQT or CYRX?

In the previous week, Cryoport had 4 more articles in the media than Arcutis Biotherapeutics. MarketBeat recorded 8 mentions for Cryoport and 4 mentions for Arcutis Biotherapeutics. Arcutis Biotherapeutics' average media sentiment score of 0.62 beat Cryoport's score of 0.51 indicating that Arcutis Biotherapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Arcutis Biotherapeutics	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Cryoport	4 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Do institutionals and insiders believe in ARQT or CYRX?

92.9% of Cryoport shares are held by institutional investors. 9.5% of Arcutis Biotherapeutics shares are held by insiders. Comparatively, 10.1% of Cryoport shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Do analysts prefer ARQT or CYRX?

Arcutis Biotherapeutics currently has a consensus price target of $16.60, indicating a potential upside of 30.91%. Cryoport has a consensus price target of $12.29, indicating a potential upside of 63.81%. Given Cryoport's higher probable upside, analysts clearly believe Cryoport is more favorable than Arcutis Biotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Arcutis Biotherapeutics	0 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.80
Cryoport	0 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.57

Summary

Cryoport beats Arcutis Biotherapeutics on 12 of the 17 factors compared between the two stocks.